+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2026-2032- Product Image
Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2026-2032- Product Image
Sale

Adeno-Associated Virus Vector Production CDMO Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118405
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Adeno-Associated Virus Vector Production CDMO Market is projected to reach USD 2.50 Billion in 2026. It is expected to continue growing at a CAGR of 13.60%, reaching USD 5.25 Billion by 2032.

Adeno-Associated Virus Vector Production CDMO: Executive Overview

Adeno-associated virus (AAV) vector production contract development and manufacturing organizations (CDMOs) support the development, process transfer, manufacturing, testing, and release of viral-vector products used in gene therapy research and clinical development. Their role spans upstream production, downstream purification, analytical characterization, quality systems, and regulatory documentation. Demand is shaped by the complexity of AAV manufacturing, the need for reproducible processes, and sponsor requirements for scalable, compliant external capacity.

Manufacturing Complexity Is Reshaping AAV CDMO Requirements

The AAV CDMO landscape is being reshaped by pressure to improve process robustness, manage empty and full capsid populations, reduce batch variability, and strengthen comparability across development stages. Sponsors increasingly require integrated support from cell-line or plasmid considerations through purification, formulation, fill-finish coordination, and release testing. Single-use systems, closed processing, automation, and platform approaches can help improve consistency, while demand for specialized serotypes and more challenging payloads increases the need for adaptable process-development capabilities.

Regulatory expectations are also encouraging earlier attention to critical quality attributes, contamination control, traceability, and data integrity. CDMOs that can provide transparent technology transfer, well-defined change-control procedures, and reliable analytical comparability are better positioned to support programs moving from research into clinical manufacturing.

Artificial Intelligence Improves Process Development, Quality, and Scheduling

Artificial intelligence can contribute to AAV vector production by identifying relationships among process parameters, impurity profiles, yield, potency, and product quality. Machine-learning tools may support experimental design, predictive process monitoring, deviation investigation, and optimization of purification conditions. Computer vision and advanced analytics can also assist environmental monitoring, equipment inspection, and laboratory workflow management.

The practical value of AI depends on data quality, validated workflows, model explainability, cybersecurity, and human oversight. In regulated manufacturing, AI outputs must be governed through documented validation, audit trails, access controls, and change management. Near-term adoption is therefore most credible in decision-support applications that complement established quality systems rather than replace accountable technical judgment.

Regional Insights: Capacity, Regulation, and Technical Expertise Differ

North America combines deep gene-therapy development activity with mature biopharmaceutical manufacturing infrastructure and strong demand for regulated clinical supply. Europe offers extensive scientific and manufacturing expertise, while regulatory and reimbursement environments differ across national jurisdictions. Asia-Pacific is expanding its advanced-biomanufacturing capabilities, with Japan, China, South Korea, Australia, and India contributing distinct regulatory, technical, and investment profiles.

Latin America remains important for regional clinical-development networks and specialized pharmaceutical services, although infrastructure and regulatory maturity vary by country. The Middle East is developing life-science and localization capabilities, particularly where public investment supports advanced healthcare manufacturing. Africa presents longer-term opportunities linked to biotechnology capacity building, but access to specialized viral-vector infrastructure, talent, and consistent supply-chain support remains uneven.

Group Insights: Trade Alignment and Regulatory Coordination Shape Access

ASEAN markets reflect varied levels of biomanufacturing maturity, with opportunities linked to regional clinical development, technology transfer, and pharmaceutical localization. BRICS members combine substantial scientific and industrial resources with differing regulatory systems, investment priorities, and access to specialized inputs. The European Union benefits from coordinated frameworks alongside national implementation differences, making cross-border quality and regulatory planning important.

The G7 economies generally provide advanced research ecosystems, experienced regulators, and established quality infrastructure. GCC countries are investing in healthcare diversification and local manufacturing, creating interest in technology partnerships and workforce development. NATO members represent a broad network of advanced economies and research institutions, but procurement, export controls, and national regulatory requirements can still affect collaboration and supply continuity.

Country Insights: Capabilities and Operating Conditions Vary Across Priority Markets

The United States and Canada offer advanced clinical-development ecosystems, specialized manufacturing talent, and extensive experience with regulated biologics. Germany, France, Italy, Spain, and the United Kingdom contribute strong research, pharmaceutical, and regulatory capabilities, while sponsors must account for differences in national execution, contracting, and clinical-supply pathways. Australia combines sophisticated clinical research with geographic considerations affecting logistics and supply planning.

China, Japan, and South Korea have significant biotechnology and biopharmaceutical capabilities, with country-specific requirements for regulatory engagement, data, technology transfer, and local operations. India is strengthening biologics manufacturing and analytical capacity while serving a broad pharmaceutical base. Brazil and Mexico are important Latin American markets with growing biotechnology and clinical-development activity. Russia’s operating environment is influenced by regulatory, trade, and geopolitical constraints, requiring careful assessment of sourcing, compliance, and continuity risks.

Actions for Leaders: Build Flexible, Data-Driven, and Regulation-Ready Partnerships

Industry leaders should evaluate CDMOs against a complete technical and quality framework rather than manufacturing price alone. Priorities include demonstrated AAV process capability, analytical depth, contamination-control performance, technology-transfer discipline, capacity transparency, supply-chain resilience, and clear responsibility for deviations and comparability. Sponsors should define critical quality attributes and acceptance criteria early, establish stage-appropriate process-control strategies, and test scale-up assumptions before pivotal commitments.

Partnerships should include detailed governance for data integrity, change control, intellectual property, business continuity, and regulatory submissions. Leaders should also assess regional redundancy for critical materials and services, qualify alternative suppliers where practical, and use digital systems to improve batch visibility. AI investments should begin with high-value, auditable use cases supported by validated data pipelines, cybersecurity controls, and accountable expert review.

Methodology: Evidence-Based Assessment of AAV CDMO Operating Conditions

This executive summary uses a structured qualitative assessment of the AAV vector production CDMO value chain. The analysis considers process-development requirements, upstream and downstream manufacturing, analytical testing, quality and regulatory expectations, technology adoption, supply-chain dependencies, and regional operating conditions. Regional, group, and country perspectives are integrated to reflect differences in scientific infrastructure, regulation, localization priorities, and cross-border execution.

Interpretation is limited to established industry dynamics and does not provide market estimates, market sizing, market shares, or forecasts. Findings should be validated against current regulatory guidance, facility-specific capabilities, sponsor requirements, and the status of individual clinical programs before operational or investment decisions are made.

Conclusion: Operational Excellence Will Differentiate AAV CDMO Partnerships

AAV vector production CDMOs are becoming strategic partners in gene-therapy development rather than transactional manufacturing providers. Success increasingly depends on reliable process transfer, strong analytical characterization, scalable purification, rigorous quality systems, and the ability to coordinate work across jurisdictions. Regional capability differences and evolving regulatory requirements make partner selection and supply-chain planning central to program execution.

Leaders that combine flexible manufacturing platforms with disciplined governance, transparent data, resilient sourcing, and carefully controlled digital innovation can better manage development complexity. The most durable partnerships will align technical capability with program stage, regulatory strategy, and long-term product-quality objectives.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Adeno-Associated Virus Vector Production CDMO Market, by Service Type
7.1. Introduction
7.2. Analytical Services
7.2.1. Potency Assay
7.2.2. Purity Assay
7.3. Downstream Processing
7.3.1. Chromatography
7.3.1.1. Affinity Chromatography
7.3.1.2. Ion Exchange Chromatography
7.3.2. Ultrafiltration
7.4. Fill Finish
7.4.1. Pre Fill Syringe
7.4.2. Vial Filling
7.5. Upstream Processing
7.5.1. Stable Expression
7.5.2. Transient Transfection
8. Adeno-Associated Virus Vector Production CDMO Market, by Production Scale
8.1. Introduction
8.2. Clinical
8.2.1. Phase One
8.2.2. Phase Three
8.2.3. Phase Two
8.3. Commercial
8.4. Preclinical
9. Adeno-Associated Virus Vector Production CDMO Market, by Production Platform
9.1. Introduction
9.2. Stable Producer Cell Line
9.3. Transient Transfection
9.3.1. Liposome Transfection
9.3.2. Polyethylenimine Transfection
10. Adeno-Associated Virus Vector Production CDMO Market, by Serotype
10.1. Introduction
10.2. AAV2
10.3. AAV8
10.4. AAV9
11. Adeno-Associated Virus Vector Production CDMO Market, by Therapeutic Application
11.1. Introduction
11.2. Genetic Diseases
11.2.1. Hemophilia
11.2.2. Muscular Dystrophy
11.3. Neurological Disorders
11.3.1. Alzheimers Disease
11.3.2. Parkinsons Disease
11.4. Oncology
12. Adeno-Associated Virus Vector Production CDMO Market, by End User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Biotechnology Companies
12.4. Pharmaceutical Companies
13. Adeno-Associated Virus Vector Production CDMO Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Adeno-Associated Virus Vector Production CDMO Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Adeno-Associated Virus Vector Production CDMO Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AGC Biologics Co., Ltd.
17.2. Aldevron, LLC
17.3. BioCentriq, Inc.
17.4. Catalent, Inc.
17.5. Charles River Laboratories International, Inc.
17.6. Creative Biogene, Inc.
17.7. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
17.8. Genezen Laboratories, Inc.
17.9. GenScript Biotech Corporation
17.10. Kaneka Eurogentec S.A.
17.11. Lonza Group AG
17.12. Merck KGaA
17.13. Novasep S.A.
17.14. Oxford Biomedica PLC
17.15. ProBio, Inc.
17.16. Resilience, Inc.
17.17. Samsung Biologics Co., Ltd.
17.18. Thermo Fisher Scientific Inc.
17.19. VGXI LLC
17.20. Wuxi AppTec Co., Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Adeno-Associated Virus Vector Production CDMO Market, Years Considered for the Study
FIGURE 2. Global Adeno-Associated Virus Vector Production CDMO Market, Research Design
FIGURE 3. Global Adeno-Associated Virus Vector Production CDMO Market, Research Framework
FIGURE 4. Global Adeno-Associated Virus Vector Production CDMO Market, Data Triangulation
FIGURE 5. Global Adeno-Associated Virus Vector Production CDMO Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2025 vs 2032 (%)
FIGURE 7. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2025 vs 2032 (%)
FIGURE 9. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2025 vs 2032 (%)
FIGURE 11. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2025 vs 2032 (%)
FIGURE 13. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 15. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Adeno-Associated Virus Vector Production CDMO Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Adeno-Associated Virus Vector Production CDMO Market Segmentation & Coverage
TABLE 2. Global Adeno-Associated Virus Vector Production CDMO Market Size, 2017-2032 (USD Million)
TABLE 3. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 4. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Potency Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Potency Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Potency Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Purity Assay Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Purity Assay Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Purity Assay Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Downstream Processing Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Downstream Processing Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Downstream Processing Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Chromatography Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Chromatography Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Chromatography Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Affinity Chromatography Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Affinity Chromatography Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Affinity Chromatography Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Ion Exchange Chromatography Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Ion Exchange Chromatography Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Ion Exchange Chromatography Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Ultrafiltration Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Ultrafiltration Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Ultrafiltration Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Fill Finish Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Fill Finish Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Fill Finish Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Pre Fill Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Pre Fill Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Pre Fill Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Vial Filling Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Vial Filling Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Vial Filling Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Upstream Processing Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Upstream Processing Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Upstream Processing Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Stable Expression Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Stable Expression Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Stable Expression Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Transient Transfection Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Transient Transfection Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Transient Transfection Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 47. Global Clinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Clinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Clinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Phase One Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Phase One Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Phase One Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Phase Three Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Phase Three Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Phase Three Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Phase Two Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Phase Two Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Phase Two Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 66. Global Stable Producer Cell Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Stable Producer Cell Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Stable Producer Cell Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Transient Transfection Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Transient Transfection Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Transient Transfection Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Liposome Transfection Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Liposome Transfection Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Liposome Transfection Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Polyethylenimine Transfection Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Polyethylenimine Transfection Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Polyethylenimine Transfection Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 79. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 89. Global Genetic Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Genetic Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Genetic Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Hemophilia Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Hemophilia Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Hemophilia Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Alzheimers Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Alzheimers Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Alzheimers Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Parkinsons Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Global Parkinsons Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. Global Parkinsons Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 107. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 110. Global Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 111. Global Academic Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Academic Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Academic Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 116. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 117. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 118. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 120. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 130. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 131. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 139. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 140. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 141. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 142. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 143. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 144. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 145. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 146. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 147. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 148. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 149. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 150. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 151. North America Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 152. North America Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 155. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 156. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 157. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 158. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 159. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 160. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 161. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 162. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 163. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 164. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 165. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 166. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 167. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 168. Latin America Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 171. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 172. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 173. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 174. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 175. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 176. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 177. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 178. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 179. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 180. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 181. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 182. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 183. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 184. Europe Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 186. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 187. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 188. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 189. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 190. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 191. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 192. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 193. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 194. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 195. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 196. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 197. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 198. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 199. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 200. Middle East Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 202. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 203. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 204. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 205. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 206. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 207. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 208. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 209. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 210. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 211. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 212. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 213. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 214. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 215. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 216. Africa Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Global Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 220. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 221. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 222. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 223. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 224. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 225. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 226. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 227. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 228. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 229. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 230. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 231. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 232. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 233. ASEAN Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 234. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 236. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 237. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 238. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 239. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 240. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 241. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 242. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 243. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 244. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 245. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 246. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 247. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 248. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 249. GCC Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 251. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 252. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 253. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 254. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 255. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 256. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 257. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 258. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 259. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 260. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 261. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 262. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 263. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 264. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 265. European Union Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 266. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 267. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 268. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 269. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 270. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 271. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 272. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 273. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 274. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 275. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 276. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 277. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 278. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 279. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 280. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 281. BRICS Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 283. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 284. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 285. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 286. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 287. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 288. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Processing, 2017-2032 (USD Million)
TABLE 289. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 290. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Clinical, 2017-2032 (USD Million)
TABLE 291. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Production Platform, 2017-2032 (USD Million)
TABLE 292. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Transient Transfection, 2017-2032 (USD Million)
TABLE 293. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Serotype, 2017-2032 (USD Million)
TABLE 294. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 295. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Genetic Diseases, 2017-2032 (USD Million)
TABLE 296. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by Neurological Disorders, 2017-2032 (USD Million)
TABLE 297. G7 Adeno-Associated Virus Vector Production CDMO Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 299. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 300. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 301. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Downstream Processing, 2017-2032 (USD Million)
TABLE 302. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Chromatography, 2017-2032 (USD Million)
TABLE 303. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Fill Finish, 2017-2032 (USD Million)
TABLE 304. NATO Adeno-Associated Virus Vector Production CDMO Market Size, by Upstream Proc

Companies Mentioned

  • AGC Biologics Co., Ltd.
  • Aldevron, LLC
  • BioCentriq, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene, Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Genezen Laboratories, Inc.
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group AG
  • Merck KGaA
  • Novasep S.A.
  • Oxford Biomedica PLC
  • ProBio, Inc.
  • Resilience, Inc.
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • VGXI LLC
  • Wuxi AppTec Co., Ltd.

Related Topics

Related Reports

Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations - Global Strategic Business Report - Product Image

Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations - Global Strategic Business Report

  • Report
  • 455 Pages
  • Global
From
Adeno Associated Virus Vector Manufacturing - Global Strategic Business Report - Product Image

Adeno Associated Virus Vector Manufacturing - Global Strategic Business Report

  • Report
  • 205 Pages
  • Global
From
Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Adeno Associated Virus Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032 - Product Image

Viral Vector & Plasmid DNA Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Adeno-Associated Virus (AAV) CDMO Market Outlook 2026-2034: Market Share and Growth Analysis by Service Type, Serotype, Manufacturing Scale, Application - Product Image

Adeno-Associated Virus (AAV) CDMO Market Outlook 2026-2034: Market Share and Growth Analysis by Service Type, Serotype, Manufacturing Scale, Application

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.